- SPACs, biotechnology and deals where insiders buy out minority investors are all at the more complex end of company finance. Roivant Sciences has found a way to combine all three.
- Roivant has about 58% of Immunovant, which at $1.5 billion is worth two-thirds less than it was at the end of last year, thanks mostly to a hitch in trials of its lead drug for autoimmune disease.
- Roivant is raising money through its own go-public merger with another SPAC, Montes Archimedes Acquisition Corp. (MAAC).
For further details see:
Roivant Double-SPAC Deal Wallows In Own Cleverness